Vera Therapeutics’ atacicept shows positive Phase 2b data in IgA nephropathy

Vera Therapeutics announced positive 72-week data from the open label extension – OLE – period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy, or IgAN. In aggregate, the 72-week data with atacicept are consistent with a profile of true disease modification in IgAN. Participants treated with atacicept for 72 weeks demonstrated a 62% reduction in Gd-IgA1, a reduction in the percentage of participants with hematuria to 19%, and a 48% reduction in UPCR in the per-protocol analysis. Participants had consistent and stable eGFR with 0 mL/min/1.73m2 change from baseline at 72 weeks. Participants who switched from placebo to atacicept demonstrated similar outcomes across each of the key indicators of IgAN. In addition, eGFR stabilization was observed in participants who switched from placebo to atacicept with a -3.2 mL/min/1.73m2 change from baseline at 72 weeks compared to -4.9 mL/min/1.73m2 at 36 weeks. Safety data in the OLE were consistent with the randomized period and indicated that atacicept was generally well-tolerated.